What does this research mean for the field?

While interstitial lung disease (ILD) providers are highly motivated to adopt peripheral blood leukocyte telomere length (PBL-TL) testing, its clinical integration is hindered by modifiable structural and knowledge barriers including cost, lack of guidelines, and workflow inefficiencies. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This study aims to identify barriers and facilitators that affect the clinical adoption of telomere length testing in interstitial lung disease.

May 20, 2026American Journal of Respiratory and Critical Care Medicine

A15-08 Bridging the Gap Between Genomic Discovery and Clinical Practice: Barriers and Facilitators to Telomere Length Testing in Interstitial Lung Disease

View Full Paper

Ask AI

Bookmark

Authors

EFE D Farrand CNC Newton CGC K Garcia

Discussion

Member takes

Overview

Mixed-methods study identifies challenges and motivations for adopting telomere length testing in ILD, suggesting actionable strategies.

Key Points

This study aims to identify barriers and facilitators that affect the clinical adoption of telomere length testing in interstitial lung disease.
Conducted a mixed-methods study with explanatory sequential data collection.
Phase 1 involved a national survey of clinicians from the Pulmonary Fibrosis Foundation Care Center Network.
Phase 2 included surveys and interviews with providers in a multi-center pragmatic observational study of PBL-TL testing.
Key facilitators included strong clinician motivation (84%) and belief in PBL-TL's value for diagnostics (84%) and prognostics (91%).
Primary barriers involved cost issues (77%), limited guidance on testing indications (72%), and workflow inefficiencies (67%).
A lack of clinical guidelines (93%) was identified as an additional significant barrier in Phase 2.

Cite This Study

Farrand et al. (2026) studied this question.

synapsesocial.com/papers/6a0d4f4cf03e14405aa9a9a3 https://doi.org/10.1093/ajrccm/aamag162.2206

View Full Paper

Ask AI

Bookmark

May 20, 2026American Journal of Respiratory and Critical Care Medicine

A15-08 Bridging the Gap Between Genomic Discovery and Clinical Practice: Barriers and Facilitators to Telomere Length Testing in Interstitial Lung Disease

View Full Paper

Ask AI

Bookmark

Authors

EFE D Farrand CNC Newton CGC K Garcia

Discussion

Member takes

Overview

Mixed-methods study identifies challenges and motivations for adopting telomere length testing in ILD, suggesting actionable strategies.

Key Points

This study aims to identify barriers and facilitators that affect the clinical adoption of telomere length testing in interstitial lung disease.
Conducted a mixed-methods study with explanatory sequential data collection.
Phase 1 involved a national survey of clinicians from the Pulmonary Fibrosis Foundation Care Center Network.
Phase 2 included surveys and interviews with providers in a multi-center pragmatic observational study of PBL-TL testing.
Key facilitators included strong clinician motivation (84%) and belief in PBL-TL's value for diagnostics (84%) and prognostics (91%).
Primary barriers involved cost issues (77%), limited guidance on testing indications (72%), and workflow inefficiencies (67%).
A lack of clinical guidelines (93%) was identified as an additional significant barrier in Phase 2.

Cite This Study

Farrand et al. (2026) studied this question.

synapsesocial.com/papers/6a0d4f4cf03e14405aa9a9a3 https://doi.org/10.1093/ajrccm/aamag162.2206

View Full Paper

Ask AI

Bookmark